Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: Results of a nationwide survey of the German Dermatologic Co-operative Oncology Group

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 7, 2007, Pages 437-444

  Terheyden, P ^a   Kortum A K ^a   Schulze, H J ^b   Durani, B ^c   Remling, R ^d   Mauch, C ^e   Junghans, V ^f   Schadendorf, D ^g   Beiteke, U ^h   Junger M ⁱ   Becker, J C ^a   Brocker E B ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Hornheide Specialist Hospital   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g Klinische Kooperationseinheit Dermatologische Onkologie des Deutschen Krebsforschungszentrums ^*  (Germany)

^h Neurologische Klinik Dortmund   (Germany)

ⁱ UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Contact dermatitis; Dinitrochlorobenzene; Melanoma; Metastasis; Tumor immunity

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; DACARBAZINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DINITROCHLOROBENZENE; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; IRRITANTS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34249030031     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-006-0182-9     Document Type: Article

References (32)

1. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzales Larriba JL, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118-1125
2. Bach AG, Marsch WC, Richter C, Lübbe D, Helmbold P (2005) Langfristig lokal rezidiviertes malignes Melanom. Hautarzt 56:949-954
3. Balch CM, Buzaid AC, Soong S-J, Atkins AB, Cascinelli N, Coit DC, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm FM, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Comittee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
4. Becker JC, Kämpgen E, Bröcker EB (2000) Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 25:503-508
5. Budzanowska E, Pawlicki M (1988) An attempt at topical DNCB immunomodulation in advanced malignant melanoma. Tumori 74:519-522
6. Burg G, Braun-Falco O (1977) 1-Chlor-2, 4-dinitrobenzol(DNCB)-Salbe zur Sensibilisierung, Testung und Behandlung von Patienten mit malignem Melanom. Dtsch Med Wochenschr 102:210-211
7. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernsthoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751
8. Drepper H, Biess B, Hofherr B, Hundeiker M, Lippold A, Otto F, Padberg G, Peters A, Wiebelt H (1993) The prognosis of patients with stage III melanoma. Prospective long-term study of 286 patients of the Fachklinik Hornheide. Cancer 71:1239-1246
9. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos N, Plager C, Burgess A, Bedikian A, Ring S, Dong Q, Glassman A, Balch CM, Benjamin RS (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103-1111
10. Flaherty LE, Liu PY, Unger J, Sondak VK (1997) Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. Am J Clin Oncol 20:600-604
11. Göring HD, Ziemer A, Kröning Y, Trebing D, Kämpgen E, Bröcker EB (1998) Effective combined immunotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma. Melanoma Res 8:379
12. Haffner AC, Garbe C, Burg G, Buttner P, Orfanos CE, Rassner G (1992) The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer 66:856-861
13. Illig L, Paul E (1976) Unspezifische epifokale Immuntherapie des malignen Melanoms der Haut mit DNCB nach Malek-Mansour. Hautarzt 27:579-587
14. Illig L, Paul E, Bödeker RH (1984) Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years). Anticancer Res 4:293-298
15. Inbar M, Merimsky O, Stein JA (1996) DNCB for local control of malignant melanoma: don't forget a winning horse. Melanoma Res 6:457-459
16. Junghans V, Menzel S, Rünger TM (1998) Erfolgreiche Therapie mit Dacarbazin und lokaler Applikation des Kontaktallergens Dinitrochlorbenzol bei therapieresistentem, in-transit- und fernmetastasiertem Melanom. Aktuelle Derm 24:332-335
17. Khayat D, Bernard-Marty C, Meric J-B, Rixe O (2002) Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol 20:2411-2414
18. Kroon BBR, Noorda EM, Vrouenraets BC, Nieweg OE (2002) Isolated limb perfusion for melanoma. J Surg Oncol 79:252-255
19. Loth H, Ehring F (1978) Die Behandlung des malignen Melanoms mit Dinitrochlorbenzol-Salbe. Hautarzt 29:141-146
20. Malek-Mansour S (1973) Remission of melanoma with DNCB treatment. Lancet 2:503-504
21. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C (2002) Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147:62-70
22. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166
23. von Nida J, Quirk C (2003) Successful treatment of in-transit metastases using topical 2-4 dinitrochlorobenzene. Australas J Dermatol 44:277-280
24. Rümke P (1992) Melanoma treatment: a key role for immunotherapy with chemotherapy. Medicographia 14:47-49
25. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tuttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler G (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563-570
26. Schuler-Thurner B, Schuler G (2005) Vaccination therapy of melanoma. JDDG 3:630-645
27. Strobbe LJA, Hart AAM, Rümke Ph, Israels SP, Nieweg OE, Kroon BBR (1997) Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 7:507-512
28. Trcka J, Kämpgen E, Becker JC, Schwaaf A, Bröcker EB (1998) Immunochemotherapie des malignen Melanoms: Epifokale Applikation von Dinitrochlorobenzol (DNCB) kombiniert mit systemischer Chemotherapie mit Dacarbazin (DTIC). Hautarzt 49:17-22
29. Trefzer U, Sterry W (2005) Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma. Dermatology 211:370-371
30. Truchetet F, Heid E, Friedel J, Chartier C, Grosshans E (1989) D.N.C.B. for malignant melanoma: significance in the treatment strategy. Anticancer Res 9:1531-1536
31. Wack C, Becker JC, Bröcker EB, Lutz WK, Fischer WH (2001) Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: results from a murine tumour model. Melanoma Res 11:247-253
32. Wack C, Kirst A, Becker JC, Lutz WK, Bröcker EB, Fischer WH (2002) Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response. Cancer Immunol Immunother 51:431-439